|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US6222020B1
(en)
|
1987-01-07 |
2001-04-24 |
Imperial Cancer Research Technology Limited |
Antigens derived from the core protein of the human mammary epithelial mucin
|
|
IL115156A
(en)
*
|
1994-09-06 |
2000-07-16 |
Univ Georgia |
Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
|
|
FR2751343B1
(fr)
|
1996-07-16 |
1998-12-18 |
Transgene Sa |
Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
|
|
CA2261989C
(en)
|
1996-07-25 |
2008-09-30 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
|
EP0931158A1
(en)
|
1996-09-06 |
1999-07-28 |
The Trustees Of The University Of Pennsylvania |
An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
|
|
EP1012276A2
(en)
|
1997-02-24 |
2000-06-28 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against muc1 tumor-associated antigen
|
|
WO1998056415A1
(en)
|
1997-06-11 |
1998-12-17 |
Aquila Biopharmaceuticals, Inc. |
Purified saponins as oral adjuvants
|
|
CA2799545A1
(en)
|
2000-03-07 |
2001-09-13 |
Merck Sharp & Dohme Corp. |
Adenovirus formulations
|
|
NZ533302A
(en)
|
2001-12-10 |
2005-11-25 |
Bavarian Nordic As |
Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions containing a disaaccharide and a pharmaceutically acceptable polymer i.e. dextran or polyvinylpyrrolidon (PVP)
|
|
US20040009951A1
(en)
*
|
2002-06-13 |
2004-01-15 |
Malim Michael H |
DNA deamination mediates innate immunity to (retro)viral infection
|
|
EP1528101A1
(en)
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
|
FR2884255B1
(fr)
|
2005-04-11 |
2010-11-05 |
Vivalis |
Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
|
|
BRPI0618850A2
(pt)
|
2005-11-21 |
2011-09-13 |
Sanofi Pasteur Ltd |
formulações de estabilização para vìrus recombinantes
|
|
GB0607063D0
(en)
*
|
2006-04-07 |
2006-05-17 |
Cellcentric Ltd |
Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
|
|
ES2611975T3
(es)
|
2006-06-20 |
2017-05-11 |
Transgene S.A. |
Procedimiento para producir poxvirus y composiciones de poxvirus
|
|
EP2029169A2
(en)
|
2006-06-20 |
2009-03-04 |
Transgene S.A. |
Recombinant viral vaccine
|
|
GB0705245D0
(en)
|
2007-03-19 |
2007-04-25 |
Stabilitech Ltd |
Stable biological products
|
|
EP1985305A1
(en)
|
2007-04-24 |
2008-10-29 |
Vivalis |
Duck embryonic derived stem cell lines for the production of viral vaccines
|
|
CA2676149C
(en)
|
2007-05-14 |
2016-06-21 |
Bavarian Nordic A/S |
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
|
|
WO2008156655A2
(en)
*
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
|
|
US8357531B2
(en)
|
2007-07-03 |
2013-01-22 |
Transgene S.A. |
Immortalized avian cell lines
|
|
KR101039235B1
(ko)
*
|
2007-08-29 |
2011-06-07 |
메디포스트(주) |
제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
|
|
AU2008328258B2
(en)
|
2007-11-19 |
2013-09-26 |
Transgene Sa |
Poxviral oncolytic vectors
|
|
US8778328B2
(en)
|
2007-11-19 |
2014-07-15 |
Transgene S.A. |
Poxviral oncolytic vectors
|
|
CN102257134B
(zh)
|
2008-02-12 |
2014-03-05 |
赛诺菲巴斯德有限公司 |
使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
|
|
JP2012509678A
(ja)
|
2008-11-27 |
2012-04-26 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
組換えウイルス発現のためのプロモーター
|
|
US8394385B2
(en)
|
2009-03-13 |
2013-03-12 |
Bavarian Nordic A/S |
Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
|
|
JP5684787B2
(ja)
|
2009-04-06 |
2015-03-18 |
大塚製薬株式会社 |
シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
|
|
ES2628580T3
(es)
|
2009-04-06 |
2017-08-03 |
Otsuka Pharmaceutical Co., Ltd. |
Combinación de decitabina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer el tratamiento de cáncer
|
|
KR20120026526A
(ko)
|
2009-05-12 |
2012-03-19 |
트랜스진 에스.에이. |
불멸화 조류 세포주 및 그의 용도
|
|
JP2013514779A
(ja)
|
2009-12-18 |
2013-05-02 |
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ |
脱メチル化および細胞の再プログラミングを促進するためのシチジンデアミナーゼ関連薬剤の使用
|
|
GB201006405D0
(en)
|
2010-04-16 |
2010-06-02 |
Isis Innovation |
Poxvirus expression system
|
|
WO2013022764A1
(en)
|
2011-08-05 |
2013-02-14 |
David Kirn |
Methods and compositions for production of vaccina virus
|
|
FI20115914L
(fi)
*
|
2011-09-16 |
2013-03-17 |
Oncos Therapeutics Ltd |
Muunnettu onkolyyttinen virus
|
|
BR112015009320A2
(pt)
|
2012-10-28 |
2017-10-17 |
Bavarian Nordic As |
promotor pr13.5 para respostas de células t e anticorpo robustas
|